Donor Immunization Vaccination and Transfer of Donor Immunity to Bone Marrow Transplant Recipients in the Course of Allogeneic Cell Therapy for Prevention and Treatment of Relapse

  • S. Slavin
  • R. Or
  • E. Naparstek
  • A. Nagler
Conference paper


In order to benefit from protective immunity, a host must be immunocompetent. Unfortunately, immunity against infections must be frequently provided to recipients who are immunoincompetent, thus making it difficult to generate effective immune responses against potentially hazardous infections. In cases when it is unfeasible to induce a protective immune response in an immunocompromized host — either because of lack of sufficient effector cells or other components required to induce an active immune response, or else because of humoral or cellular suppressive mechanisms that prevent generation of a normal immune response by existing immune cells — a possible solution is passive adoptive transfer of cell-mediated immunity, using lymphocytes obtained from major histocompatibility (MHC) compatible donors sensitized in vivo or in vitro. The present report will summarize some of our experience in adoptive transfer of cell-mediated immune responses into recipients made tolerant of donor alloantigens in the course of bone marrow transplantation (BMT). Recent developments at our center suggest that successful induction of host vs donor tolerance in the course of allogeneic BMT procedure, which classically involves myeloablative treatment, may provide a good basis for successful intentional adoptive transfer of donor immunity to the host. Furthermore, similar results may be achieved following non-myeloablative conditioning, suggesting that safe methods, free of procedure-related toxicity, may soon become available for induction of unresponsiveness to donor-derived hematopoietic grafts, including donor-derived lymphocytes, capable of transferring donor immunity to an immunocompromized host.


Adoptive Transfer Allogeneic Bone Marrow Transplantation Donor Lymphocyte Infusion Bone Marrow Donor Bone Marrow Transplantation Recipient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mumcuoglu M, Zakay Rones Z, Parag G, Weiss L, Slavin S (1987) The effect of T lymphocyte depletion of susceptibility to influenza virus infection and development of anti-viral immunity in lethally irradiated mice reconstituted with syngeneic bone marrow grafts. Bone Marrow Transplant 2: 403–412PubMedGoogle Scholar
  2. 2.
    Avichezer D, Gilboa-Garber N, Mumcuoglu M, Slavin S (1989) Adoptive transfer of resistance to Pseudomonas aeruginosa infection by splenocytes and bone marrow cells from BALB/c mice immunized by Pseudomonas aeruginosa lectin preparations. Infection 17:407–410PubMedCrossRefGoogle Scholar
  3. 3.
    Shouval D, Adler R, Ilan Y (1993) Adoptive transfer of immunity to hepatitis B virus in mice by bone marrow transplantation from immune donors. Hepatology 17:955–959PubMedCrossRefGoogle Scholar
  4. 4.
    Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, Brautbar C, Or R (1996) Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation. Blood 87(6)12195–2204Google Scholar
  5. 5.
    Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Brautbar C, Or R (1995) Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 23:1553–1562PubMedGoogle Scholar
  6. 6.
    Horowitz M, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B (1990) Graft vs leukemia reactions after bone marrow transplantation. Blood 75:555PubMedGoogle Scholar
  7. 7.
    Porter DL, Roth MS, McGarigle C, Ferrara LM (1994) Induction of graft vs host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330:100PubMedCrossRefGoogle Scholar
  8. 8.
    Collins RH, Shpilberg O, Drobyski WR et al (1997) Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433–444PubMedGoogle Scholar
  9. 9.
    Naparstek E, Or R, Nagler A, Cividalli G, Engelhard D, Aker M, Gimon Z, Manny N, Sacks T, Tochner Z, Weiss L, Samuel S, Brautbar H, Hale G, Waldmann H, Steinberg SM, Slavin S (1995) T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-i antibodies and post-transplant administration of donor’s peripheral blood lymphocytes for prevention of relapse. Br J Haematol 89:506–515PubMedCrossRefGoogle Scholar
  10. 10.
    McDonald GB, Shulman HM, Wolford JL, Spencer GD (1987) Liver disease after human marrow transplantation. Semin Liver Dis 7:210–217PubMedCrossRefGoogle Scholar
  11. 11.
    McDonald GG, Sharma P, Matthews DE, Shulman HM, Thomas ED (1984) Venocclusive disease of the liver after BMT: diagnosis, incidence and predisposing factor. Hepatology 4:116–121PubMedCrossRefGoogle Scholar
  12. 12.
    Devergie A, Brechot C, Schenmetzler C, Bernuau J (1988) Fulminant hepatitis due to reactivitation of chronic hepatitis B virus infection after allogeneic BMT. Dig Dis Sci 33:1185–1189PubMedCrossRefGoogle Scholar
  13. 13.
    Lum LG (1987) The kinetics of immune reconstitution after human marrow transplantation. Blood 69:369–394PubMedGoogle Scholar
  14. 14.
    Witherspoon RP, Strorb R, Ochs HD, Flouronoy N, Kopecky KJ, Sullivan KM, Deeg HJ (1981) Recovery of antibody production in human allogeneic marrow graft recipients: influence of time post transplantation and anti-thymocyte globulin treatment. Blood 58:360–366PubMedGoogle Scholar
  15. 15.
    Webster A, Brenner MK, Prentice HG, Griffiths D (1989) Fatal hepatitis reactivation after autologous BMT. Bone Marrow Transplant 4:207–211PubMedGoogle Scholar
  16. 16.
    Chen PM, Fan S, Liu CJ, Hsieh RY, Lin JH, Chuan MW, Liu RS et al (1990) Changing of hepatitis B virus markers in patients with BMT. Transplantation 49:708–713PubMedCrossRefGoogle Scholar
  17. 17.
    Rosendahl C, Bender-Goetze C, Deinhardt F, Kolb HJ, Hass R (1985) Immunization against hepatitis B in BMT and leukemia patients. Exp Hematol 13 Suppl 17:104–111Google Scholar
  18. 18.
    Winston DJ, Ho WG, Schiffman G, Camplin RF, Feig SA, Gale RB (1983) Pneumococcal vaccination of recipients of BMT. Arch Intern Med 143:1735–1737PubMedCrossRefGoogle Scholar
  19. 19.
    Ljungman P, Fridell E, Longuist B, Bolme P, Bottigr M, Gahrton A, Linde O et al (1989) Efficacy and safety of vaccination of marrow transplant recipients with live attenuated measels, mumps and rubella vaccine. J Infect Dis 159:610–613PubMedCrossRefGoogle Scholar
  20. 20.
    Gottlieb DJ, Furer CE, Que JU, Prentice HG, Duncombe AS, Brenner MK (1990) Immunity against Pseudomonas aeruginosa adoptively transferred to BMT recipients. Blood 76:2470–2472PubMedGoogle Scholar
  21. 21.
    Saxon A, Mitsuyasu R, Stevens R, Champlin RE, Kimata H, Gale RP (1986) Designed transfer of specific immune responses with bone marrow transplantation. J Clin Invest 78:959–964PubMedCrossRefGoogle Scholar
  22. 22.
    Wimperis JZ, Brenner MK, Prentice HG, Reittie JE, Karayianis P, Griffiths PD (1986) Transfer of a functioning humoral immune system in transplantation of T lymphocyte depleted bone marrow. Lancet 1:339–347PubMedCrossRefGoogle Scholar
  23. 23.
    Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD (1992) Restoration of viral immunity in immunodefkient humans by adoptive transfer of T cell clones. Science 257:238–240PubMedCrossRefGoogle Scholar
  24. 24.
    Ilan Y, Nagler A, Adler R, Naparstek E, Or R, Slavin S, Brautbar C, Shouval D (1993)Adoptive transfer of immunity to hepatitis B virus after T cell depleted allogeneic BMT. Hepatology 18:246–252PubMedGoogle Scholar
  25. 25.
    Ilan Y, Nagler A, Shouval D, Ackerstein A, Or R, Kapelushnik J, Adler R, Slavin S (1994)Development of antibodies to hepatitis B virus surface antigen in bone marrow transplant recipient following treatment with peripheral blood lymphocytes from immunized donors. Clin Exp Immunol 97:299–302PubMedCrossRefGoogle Scholar
  26. 26.
    Ilan Y, Nagler A, Adler R, Tur-Kaspa R, Slavin S, Shouval D (1993) Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B immune donor: a case report. Gastroenterology 104:1818–1821PubMedGoogle Scholar
  27. 27.
    Kuzushima K, Yamamoto M, Kimura H, Ando Y, Kudo T, Tsuge I, Morishima T (1996) Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus specific cytotoxic T lymphocytes from an HLA matched sibling to a patient with severe chronic active EBV infection. Clin Exp Immunol 103:192–198PubMedCrossRefGoogle Scholar
  28. 28.
    Slavin S, Nagler A, Naparstek E, Ackerstein A, Kapelushnik J, Varadi G, Kirschbaum M, Ben-Josef R, Samuel S, Or R (1996) Immunotherapy of leukemia in conjunction with non-myeloablative conditioning engraftment of blood stem cells and eradication of host leukemia with non-myeloablative conditioning based on fludarabine and anti-thymocyte globulin (ATG) (Abstr 2443) Blood 88(10):614 aGoogle Scholar
  29. 29.
    Slavin S (1987) Total lymphoid irradiation (TLI). Immunol Today 8:88–92CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • S. Slavin
  • R. Or
  • E. Naparstek
  • A. Nagler

There are no affiliations available

Personalised recommendations